Live VYLOY National Broadcast
Loading Map....
Learn about the first CLCN18.2 targeted therapy available in the US for patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Thursday December 5, 2024 – 6:00 PT
Key Objectives:
- Educate HCPs on the administration of this monoclonal antibody
- Discuss VYLOY and its appropriate use to treat patients with CDN 81.2 positive gastric and GEJ cancers
Presented by
Ronan J. Kelly MD, MBA, FASCO
Director
Charles A. Sammons Cancer Center
Baylor University Medical Center
Dallas, TX
Michelle Shiller, DO, MSPT
Medical Director Cancer Genetics
Baylor Sammons Cancer Center
Dallas, TX
Paige Griffith, CRNP
Lead Oncology Nurse Practitioner
Johns Hopkins University
Sidney Kimmel Comprehensive Cancer
Scan the QR Code or register at: https://astellasregistration.com/vyloy/125
